Get the Stockscreener App
7.44
3.12%
-0.24
After Hours:
7.49
0.05
+0.67%
Eupraxia Pharmaceuticals Inc stock is traded at $7.44, with a volume of 41,546.
It is down -3.12% in the last 24 hours and up +18.47% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$7.68
Open:
$7.62
24h Volume:
41,546
Relative Volume:
0.36
Market Cap:
$376.82M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-9.6623
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
-1.98%
1M Performance:
+18.47%
6M Performance:
+38.03%
1Y Performance:
+148.00%
1-Day Range:
$7.3517
$7.735
1-Week Range:
$7.3517
$7.90
52-Week Range:
$2.6801
$8.00
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.44 | 388.98M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Up 0.3% – Here’s What Happened - Defense World
(EPRX.WT.A) Advanced Equity Analysis - Stock Traders Daily
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Stock Trading Blueprint - Stock Traders Daily
(EPRX) Comprehensive Trading Strategy Report (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Daily Stock Insights - Stock Traders Daily
Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December - MarketBeat
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - Stock Traders Daily
How the (EPRX.WT.A) price action is used to our Advantage - Stock Traders Daily
(EPRX) Equity Market Report (EPRX:CA) - Stock Traders Daily
562,500 Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Can Eupraxia Pharmaceuticals Inc. stock sustain institutional interest2025 Major Catalysts & Low Drawdown Trading Techniques - Улправда
Will Eupraxia Pharmaceuticals Inc. stock reach Wall Street targetsEntry Point & Community Verified Swing Trade Signals - Улправда
(EPRX) Advanced Trading Insights (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Why Eupraxia Pharmaceuticals Inc. stock is a must watch in 2025Quarterly Trade Report & Long-Term Safe Return Strategies - Улправда
Moving Averages: Why Eupraxia Pharmaceuticals Inc. stock is a must watch in 2025July 2025 News Drivers & Momentum Based Trading Ideas - Улправда
Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Signal Summary & Short-Term High Return Ideas - Улправда
Can Eupraxia Pharmaceuticals Inc. stock beat analyst upgradesMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Stock Report: Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidanceJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Why Eupraxia Pharmaceuticals Inc. stock could see breakout soonDay Trade & Risk Controlled Stock Pick Alerts - Улправда
Aug Decliners: Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolution2025 Historical Comparison & Daily Chart Pattern Signals - Улправда
Aug Final Week: How Eupraxia Pharmaceuticals Inc. stock valuations compare to rivalsTrend Reversal & High Accuracy Investment Entry Signals - Улправда
What insider trading reveals about Eupraxia Pharmaceuticals Inc. stock - DonanımHaber
How Eupraxia Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Macro Moves & AI Driven Price Predictions - DonanımHaber
How geopolitical risks impact Eupraxia Pharmaceuticals Inc. (X43) stockWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
Market Review: Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Entry Summary & Growth Oriented Trade Recommendations - Улправда
(EPRX.WT.A) Stock Evaluation Report - Stock Traders Daily
Why Eupraxia Pharmaceuticals Inc. stock remains a top recommendationProduct Launch & Intraday High Probability Alerts - DonanımHaber
Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidance2025 Risk Factors & Daily Market Momentum Tracking - Улправда
Bearish Setup: Why Eupraxia Pharmaceuticals Inc. stock could see breakout soon2025 Institutional Moves & Low Risk Entry Point Tips - Улправда
(EPRX.WT.A) Strategic Equity Report - Stock Traders Daily
How to Take Advantage of moves in (EPRX) (EPRX:CA) - news.stocktradersdaily.com
FY2025 Earnings Estimate for EPRX Issued By Lifesci Capital - MarketBeat
(EPRX.WT.A) Risk-Controlled Trading Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.3% – Here’s Why - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Strong-Buy at Lifesci Capital - Defense World
New Highs: How Eupraxia Pharmaceuticals Inc stock reacts to global recession fears2025 Historical Comparison & Fast Moving Trade Plans - moha.gov.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to "Strong-Buy" at Lifesci Capital - MarketBeat
Eupraxia Pharmaceuticals Inc. (EPRXF) Competitors - Meyka
(EPRX.WT.A) Investment Analysis and Advice - Stock Traders Daily
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Analysts see more than 77% upside for Eupraxia Pharmaceuticals (EPRX), here’s why - MSN
CapEx per share of Eupraxia Pharmaceuticals Inc Warrant 2021-09.03.2026 on Eupraxia Pharma Rg – TSX:EPRX.WT - TradingView
Is Eupraxia Pharmaceuticals Inc. stock oversold or undervaluedWeekly Trade Review & Verified Technical Signals - Newser
Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why - Finviz
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):